item management s discussion and analysis of financial condition and results of operations 
the following table sets forth various items from the consolidated statements of income as a percentage of net sales for the periods indicated year ended march  net sales cost of sales selling  general and administrative research and development operating income interest income expense  net 
other expense income before income taxes income taxes net income results of operations sales sales for fiscal increased from million in to million  an increase of 
growth was particularly strong in sales of plastic surgery products  up over the prior year  attributable to both unit growth in the market and market share gains 
sales of urology products increased  as improved sales of disposable incontinence products accelerated growth over prior years 
ophthalmic product sales increased over last year 
increased international sales of the memorylens foldable intraocular lens were offset by declines in domestic sales of fixed intraocular lens 
sales for fiscal increased to million  compared to million the prior year 
plastic surgery product sales were up over the prior year  attributable to both unit growth in the market and market share gains 
sales of urology products were flat with last year 
sales of urologic implants  however  increased in the second half of the year  due to heightened public awareness in seeking treatment for impotence 
ophthalmic product sales increased over the prior year  as increases in intraocular lens sales offset declining revenues from discontinued diagnostic equipment 
in october  the company acquired the intraocular lens iol product line of optical radiation corporation  a subsidiary of benson eyecare corporation 
this acquisition was included for the full year in fiscal  while only for six months in fiscal the company s export sales to unaffiliated customers accounted for   and of net sales in the fiscal years ended march   and  respectively 
over the three fiscal years ended march   sales increases have been primarily the result of increased unit sales and a shift to higher priced products 
general selling price increases have not been significant in recent years 
cost of sales cost of sales was for fiscal  compared to for the prior year 
the company continues to work on a variety of efficiency enhancements at each of its facilities 
in addition  the improvement in the cost of sales was aided by a greater proportion of higher margin products in the sales mix  as well as the discontinuance of low margin ophthalmic diagnostic products 
cost of sales was for fiscal  compared to for fiscal increased operating efficiencies helped compensate for the substantially higher prices the company began paying on many of its medical and implant grade materials 
these materials are now being sourced from new vendors following the exit of certain suppliers  such as dow corning and dupont  from this market 
in addition  the company s new manufacturing plant in the netherlands  which incurred startup expenses in the prior year  was in full production in fiscal selling  general and administrative selling  general and administrative expenses decreased to of sales in fiscal  compared to the prior year 
a small increase in sales marketing expense  due to new product introductions  was offset by productivity increases in administrative areas 
selling  general and administrative expenses decreased to of sales in fiscal  compared to in the previous year 
the company experienced productivity improvements in its sales efforts  particularly in the plastic surgery division 
research and development research and development expenses were of sales in fiscal  up from the prior year 
the company continues to spend substantial funds on its premarket approval applications pmaas for its silicone gel filled breast implants  saline breast implants and penile implants 
the company is committed to a variety of clinical and laboratory studies in connection with these products 
in addition  the company spent a significant amount of funds on its ultrasonic assisted liposuction product 
development dollars were also spent on the advent a b ophthalmic ultrasound and the mentor sistem phacoemusifier  introduced in fiscal other major clinical studies underway include urethrin  a product for treating urinary incontinence and the memorylens  a foldable iol 
the company expects to pursue additional clinical studies and product development in the coming year  while spending on existing projects is not expected to decline substantially 
thus the company expects to spend more in research and development as a percent of sales in fiscal than it did in fiscal research and development expenses were of sales in fiscal  compared to in fiscal interest and other income and expense interest expense was thousand in fiscal  a decrease from million in fiscal due to the conversion of the convertible subordinated debentures in fiscal  there was no interest expense incurred in  compared to thousand in fiscal included in interest expense in was thousand in imputed interest on the litigation settlement obligation  a decrease from thousand the prior year 
as the obligation was paid in full in fiscal  there will be no further expense related to this item 
interest income increased to thousand in from thousand in fiscal year  resulting from higher cash balances 
other income and expense includes primarily gains or losses on disposals of assets  and foreign currency gains or losses related to the company s foreign operations 
interest expense was million in fiscal  a decrease from million in fiscal in the first quarter of fiscal  the company called for the redemption of its convertible subordinated debentures 
as of june  the debentures had been either converted into common stock or redeemed 
included in interest expense for the year is thousand in imputed interest on the litigation settlement obligation  compared to million in the prior year 
interest income increased from thousand in to thousand in fiscal  resulting from higher cash balances 
income taxes the effective rate of corporate income taxes was for fiscal and  compared to for fiscal net income net income per primary share in fiscal was  compared to in fiscal the increase was caused by higher sales combined with an increase in net interest income 
inflation the company does not believe inflation has had a material impact on the company s operations over the three year period ended march  liquidity and capital resources during the three years ended march   liquidity needs have been satisfied principally by cash flow from operations 
at march   working capital was million compared to million the previous year 
the company generated million of cash from operations during fiscal  compared to million the previous year 
increases in net income  deferred income taxes and a reduction in growth of accounts receivable were partially offset by a slower increase in accounts payable from the prior year 
during fiscal the company spent million on capital expenditures and intangibles 
the majority of the funds was for improvements in manufacturing facilities  primarily texas and minneapolis  and equipment and data processing hardware and software 
the company anticipates investing approximately million in facilities and capital equipment in fiscal during fiscal  the company had available to it million under a secured line of credit 
borrowings accrue interest at the prevailing prime rate 
the line of credit includes certain covenants which  among others  limit the dividends the company may pay and require the maintenance of certain levels of tangible net worth and debt service ratios 
an annual commitment fee of 
is paid on the unused portion of the credit line 
there were no borrowings under the agreement in fiscal  nor any balance outstanding at march  during fiscal  the company finalized its agreement with the federal multi district litigation plaintiffs steering committee  which settled all outstanding breast implant litigation and claims against the company 
the agreement established a settlement fund of million  to be funded by the company and its insurers 
under the terms of the agreement  the company made a payment of million during fiscal  completing the company s monetary obligations under the agreement 
during fiscal  the company called for the redemption of its convertible subordinated debentures  with a redemption date of june  all but thousand of the million balance at march  was converted into common stock at a price of 
a total of  shares were issued to debenture holders 
interest accrued on the debentures but not paid as a result of the conversion million was credited  net of the applicable tax effect  directly to shareholders equity 
in fiscal  the company announced that its board of directors had authorized the repurchase of up to  shares of common stock 
the shares purchased and retired under this program will be used to offset stock options previously granted to employees of the company under existing stock option plans 
during fiscal  the company repurchased  shares for an aggregate consideration of million 
the company s principal source of liquidity at march  consisted of million in cash and marketable securities plus million available under the existing line of credit 
factors that may affect future results of operations except for the historical information contained herein  the matters discussed in this management s discussion are forward looking statements  the accuracy of which is necessarily subject to risks and uncertainties 
actual results may differ significantly from the discussion of such matters in the forward looking statements 
due to the nature of the company s products and business  the company has been and will be involved in various legal actions arising in the course of business  some of which involve product liability and intellectual property claims 
with respect to product liability issues  the litigation and regulatory risks will continue to exist even with respect to those products that have received or in the future may receive regulatory approval for commercial sale 
it is possible that adverse results arising from product liability or intellectual property actions  as well as adverse results arising from regulatory or administrative proceedings  could negatively affect the company s future results of operations 
the company has been and may be in the future the subject of negative publicity  which can arise from various sources  ranging from the news media to legislative and regulatory investigations 
there can be no assurance that such negative publicity will not result in a material adverse effect on the company s future financial position  its results of operations or the market price of its stock 
in addition  significant negative publicity could result in an increase in product liability claims 
the company s products  development activities and manufacturing processes are subject to extensive and rigorous regulation by the fda and by comparable agencies in foreign countries 
in the united states  the fda regulates the introduction  manufacturing  labeling and recordkeeping procedures for medical devices 
the process of obtaining marketing clearance from the fda for new products and existing products can be time consuming and expensive  and there is no assurance that such clearances will be granted or that fda review will not involve delays that would adversely affect the company s ability to commercialize additional products or additional applications for existing products 
in addition  certain of the company s products that are in the research and development stage may be subject to a lengthy and expensive pre market approval pma process with the fda 
product approvals by the fda can also be withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial approval 
the fda could also limit or prevent the manufacture or distribution of the company s products and has the power to require the recall of such products 
fda regulations depend heavily on administrative interpretation  and there can be no assurance that future interpretations made by the fda or other regulatory bodies will not adversely affect the company 
the fda  various state agencies and foreign regulatory agencies inspect the company and its facilities from time to time to determine whether the company is in compliance with various regulations relating to manufacturing practices  validation  testing  quality control and product labeling 
a determination that the company is in violation of such regulations could lead to imposition of penalties  product recalls or product seizures 
each of the company s major business segments operates its manufacturing  warehousing and research and development activities in a single facility 
while the company has some limited protection in the form of basic insurance coverage  the company s operating results and financial condition would be materially adversely affected in the event of a fire or similar catastrophe 

